Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00290_DB01097> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00290_DB01097 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00290_DB01097 label "DDI between Bleomycin and Leflunomide - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. [drugbank_resource:DB00290_DB01097]" assertion.
- drugbank_resource:DB00290_DB01097 identifier "drugbank_resource:DB00290_DB01097" assertion.
- drugbank_resource:DB00290_DB01097 title "DDI between Bleomycin and Leflunomide - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity." assertion.